Global  

Trusted News Discovery Since 2008
One News Page
One News Page > Business News > Paradigm Biopharmaceuticals treats first US patient with Zilosul®

Paradigm Biopharmaceuticals treats first US patient with Zilosul®

Proactive Investors Tuesday, 18 February 2020
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has dosed the first patient under the US FDA approved Expanded Access Program (EAP) with Zilosul®. The EAP provides a pathway for doctors and patients to gain access to investigational drugs such as Zilosul® to treat serious diseases or conditions for which there are no comparable or satisfactory therapy options available outside of clinical trials. Paradigm will treat 10 patients comprised of ex-NFL players under the EAP. The patients will receive two injections per week over six weeks, with the 10 patients to have staggered starts over the next 4 weeks. Dosing in-line with forthcoming Phase 3 Pivotal Study Paradigm’s CEO Paul Rennie said: “This is an important milestone for Paradigm as we continue to progress toward the commencement of the Phase 3 Pivotal Study and commercialisation of Zilosul® as a potential first line treatment for Knee Osteoarthritis. “The data collected from the 10 patients in the Extended Access Program will add strength to the data already collected from the 600+ patients Paradigm has treated throughout its successful Phase 2b clinical trials and SAS program in Australia. “We are looking forward to releasing more information in due course about the progress of the Pivotal Phase 3 Study and are hopeful that a positive experience under this EAP will help drive public interest in the forthcoming trials the company expects to conduct in 2020.” EAP similar to Australia’s SAS and collects real-world data Mitch Marrow, a former NFL Player with the Carolina Panthers was the first to be treated with iPPS, in Australia under the special access program (SAS). Marrow said: “The treatment was so life-changing in treating my years of pain and lack of mobility that I am thrilled more former NFL players will have access to this incredible drug in the US under the Expanded Access Program”.
0
shares
ShareTweetSavePostSend
 

Recent related videos from verified sources

Ecuador confirms first case of coronavirus [Video]

Ecuador confirms first case of coronavirus

Ecuador on Saturday (February 29th) confirmed the country's first case of coronavirus. The 70-year-old patient is believed to have contracted the virus in Spain and arrived in Ecuador about 15 days..

Credit: Newsflare     Duration: 01:35Published

Recent related news from verified sources

Paradigm Biopharmaceuticals in halt pending response to Food & Drug Administration update

Paradigm Biopharmaceuticals Ltd (ASX:PAR) (OTCMKTS:PBIGF) is in a trading halt pending an announcement in response to an update from the Food & Drug...
Proactive Investors

Admedus discharges first patient following clinical SAVR trial

Admedus Ltd (ASX:AHZ) has announced the hospital discharge of its first patient following its clinical surgical aortic valve replacement (SAVR) trial. On March...
Proactive Investors

You Might Like


Tweets about this



Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2020 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.